Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy

Douglas E. Peterson, Kerstin Öhrn, Joanne Bowen, Monica Fliedner, Judith Lees, Charles Loprinzi, Takehiko Mori, Anthony Osaguona, Dianna S. Weikel, Sharon Elad, Rajesh V. Lalla

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Purpose: This systematic review analyzed the strength of the literature and defined clinical practice guidelines for the use of oral cryotherapy for the prevention and/or treatment of oral mucositis caused by cancer therapy. Methods: A systematic review on relevant oral cryotherapy studies indexed prior to 31 December 2010 was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) using OVID/MEDLINE, with publications selected for review based on defined inclusion and exclusion criteria. Findings from the reviewed studies were integrated into guidelines based on the overall level of evidence for each intervention. Guidelines were classified into three types: recommendation, suggestion, or no guideline possible. Results: Twenty-two clinical studies and two meta-analyses were analyzed. Results were compared with the MASCC/ISOO guidelines published in 2007. The recommendation for the use of oral cryotherapy to prevent oral mucositis in patients receiving bolus fluorouracil (5-FU) was maintained, in agreement with the 2007 guidelines. A suggestion for use of oral cryotherapy to prevent oral mucositis in patients receiving high-dose melphalan as conditioning regimen with or without total body irradiation for HCST was revised from the 2007 guidelines. No guideline was possible for any other intervention, due to insufficient evidence. Conclusions: The evidence continues to support the use of oral cryotherapy for prevention of oral mucositis in patients receiving bolus 5-FU chemotherapy or high-dose melphalan. This intervention is consistent with the MASCC/ISOO guidelines published in 2007. The literature is limited by the fact that utilization of a double-blind study design is not feasible. Future studies that compare efficacy of oral cryotherapy with other mucositis agents in patients receiving chemotherapy with relatively short plasma half-lives would be useful.

Original languageEnglish
Pages (from-to)327-332
Number of pages6
JournalSupportive Care in Cancer
Volume21
Issue number1
DOIs
Publication statusPublished - 2013 Jan

Fingerprint

Stomatitis
Cryotherapy
Guidelines
Neoplasms
Fluorouracil
Mucositis
Melphalan
Therapeutics
Drug Therapy
Whole-Body Irradiation
Proxy
Practice Guidelines
Double-Blind Method
MEDLINE
Publications
Meta-Analysis

Keywords

  • Cancer
  • Oral cryotherapy
  • Oral mucositis

ASJC Scopus subject areas

  • Oncology

Cite this

Peterson, D. E., Öhrn, K., Bowen, J., Fliedner, M., Lees, J., Loprinzi, C., ... Lalla, R. V. (2013). Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Supportive Care in Cancer, 21(1), 327-332. https://doi.org/10.1007/s00520-012-1562-0

Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. / Peterson, Douglas E.; Öhrn, Kerstin; Bowen, Joanne; Fliedner, Monica; Lees, Judith; Loprinzi, Charles; Mori, Takehiko; Osaguona, Anthony; Weikel, Dianna S.; Elad, Sharon; Lalla, Rajesh V.

In: Supportive Care in Cancer, Vol. 21, No. 1, 01.2013, p. 327-332.

Research output: Contribution to journalArticle

Peterson, DE, Öhrn, K, Bowen, J, Fliedner, M, Lees, J, Loprinzi, C, Mori, T, Osaguona, A, Weikel, DS, Elad, S & Lalla, RV 2013, 'Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy', Supportive Care in Cancer, vol. 21, no. 1, pp. 327-332. https://doi.org/10.1007/s00520-012-1562-0
Peterson, Douglas E. ; Öhrn, Kerstin ; Bowen, Joanne ; Fliedner, Monica ; Lees, Judith ; Loprinzi, Charles ; Mori, Takehiko ; Osaguona, Anthony ; Weikel, Dianna S. ; Elad, Sharon ; Lalla, Rajesh V. / Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. In: Supportive Care in Cancer. 2013 ; Vol. 21, No. 1. pp. 327-332.
@article{6f64fc49a9a245b7877b1603fc77d1ee,
title = "Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy",
abstract = "Purpose: This systematic review analyzed the strength of the literature and defined clinical practice guidelines for the use of oral cryotherapy for the prevention and/or treatment of oral mucositis caused by cancer therapy. Methods: A systematic review on relevant oral cryotherapy studies indexed prior to 31 December 2010 was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) using OVID/MEDLINE, with publications selected for review based on defined inclusion and exclusion criteria. Findings from the reviewed studies were integrated into guidelines based on the overall level of evidence for each intervention. Guidelines were classified into three types: recommendation, suggestion, or no guideline possible. Results: Twenty-two clinical studies and two meta-analyses were analyzed. Results were compared with the MASCC/ISOO guidelines published in 2007. The recommendation for the use of oral cryotherapy to prevent oral mucositis in patients receiving bolus fluorouracil (5-FU) was maintained, in agreement with the 2007 guidelines. A suggestion for use of oral cryotherapy to prevent oral mucositis in patients receiving high-dose melphalan as conditioning regimen with or without total body irradiation for HCST was revised from the 2007 guidelines. No guideline was possible for any other intervention, due to insufficient evidence. Conclusions: The evidence continues to support the use of oral cryotherapy for prevention of oral mucositis in patients receiving bolus 5-FU chemotherapy or high-dose melphalan. This intervention is consistent with the MASCC/ISOO guidelines published in 2007. The literature is limited by the fact that utilization of a double-blind study design is not feasible. Future studies that compare efficacy of oral cryotherapy with other mucositis agents in patients receiving chemotherapy with relatively short plasma half-lives would be useful.",
keywords = "Cancer, Oral cryotherapy, Oral mucositis",
author = "Peterson, {Douglas E.} and Kerstin {\"O}hrn and Joanne Bowen and Monica Fliedner and Judith Lees and Charles Loprinzi and Takehiko Mori and Anthony Osaguona and Weikel, {Dianna S.} and Sharon Elad and Lalla, {Rajesh V.}",
year = "2013",
month = "1",
doi = "10.1007/s00520-012-1562-0",
language = "English",
volume = "21",
pages = "327--332",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy

AU - Peterson, Douglas E.

AU - Öhrn, Kerstin

AU - Bowen, Joanne

AU - Fliedner, Monica

AU - Lees, Judith

AU - Loprinzi, Charles

AU - Mori, Takehiko

AU - Osaguona, Anthony

AU - Weikel, Dianna S.

AU - Elad, Sharon

AU - Lalla, Rajesh V.

PY - 2013/1

Y1 - 2013/1

N2 - Purpose: This systematic review analyzed the strength of the literature and defined clinical practice guidelines for the use of oral cryotherapy for the prevention and/or treatment of oral mucositis caused by cancer therapy. Methods: A systematic review on relevant oral cryotherapy studies indexed prior to 31 December 2010 was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) using OVID/MEDLINE, with publications selected for review based on defined inclusion and exclusion criteria. Findings from the reviewed studies were integrated into guidelines based on the overall level of evidence for each intervention. Guidelines were classified into three types: recommendation, suggestion, or no guideline possible. Results: Twenty-two clinical studies and two meta-analyses were analyzed. Results were compared with the MASCC/ISOO guidelines published in 2007. The recommendation for the use of oral cryotherapy to prevent oral mucositis in patients receiving bolus fluorouracil (5-FU) was maintained, in agreement with the 2007 guidelines. A suggestion for use of oral cryotherapy to prevent oral mucositis in patients receiving high-dose melphalan as conditioning regimen with or without total body irradiation for HCST was revised from the 2007 guidelines. No guideline was possible for any other intervention, due to insufficient evidence. Conclusions: The evidence continues to support the use of oral cryotherapy for prevention of oral mucositis in patients receiving bolus 5-FU chemotherapy or high-dose melphalan. This intervention is consistent with the MASCC/ISOO guidelines published in 2007. The literature is limited by the fact that utilization of a double-blind study design is not feasible. Future studies that compare efficacy of oral cryotherapy with other mucositis agents in patients receiving chemotherapy with relatively short plasma half-lives would be useful.

AB - Purpose: This systematic review analyzed the strength of the literature and defined clinical practice guidelines for the use of oral cryotherapy for the prevention and/or treatment of oral mucositis caused by cancer therapy. Methods: A systematic review on relevant oral cryotherapy studies indexed prior to 31 December 2010 was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) using OVID/MEDLINE, with publications selected for review based on defined inclusion and exclusion criteria. Findings from the reviewed studies were integrated into guidelines based on the overall level of evidence for each intervention. Guidelines were classified into three types: recommendation, suggestion, or no guideline possible. Results: Twenty-two clinical studies and two meta-analyses were analyzed. Results were compared with the MASCC/ISOO guidelines published in 2007. The recommendation for the use of oral cryotherapy to prevent oral mucositis in patients receiving bolus fluorouracil (5-FU) was maintained, in agreement with the 2007 guidelines. A suggestion for use of oral cryotherapy to prevent oral mucositis in patients receiving high-dose melphalan as conditioning regimen with or without total body irradiation for HCST was revised from the 2007 guidelines. No guideline was possible for any other intervention, due to insufficient evidence. Conclusions: The evidence continues to support the use of oral cryotherapy for prevention of oral mucositis in patients receiving bolus 5-FU chemotherapy or high-dose melphalan. This intervention is consistent with the MASCC/ISOO guidelines published in 2007. The literature is limited by the fact that utilization of a double-blind study design is not feasible. Future studies that compare efficacy of oral cryotherapy with other mucositis agents in patients receiving chemotherapy with relatively short plasma half-lives would be useful.

KW - Cancer

KW - Oral cryotherapy

KW - Oral mucositis

UR - http://www.scopus.com/inward/record.url?scp=84874112881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874112881&partnerID=8YFLogxK

U2 - 10.1007/s00520-012-1562-0

DO - 10.1007/s00520-012-1562-0

M3 - Article

VL - 21

SP - 327

EP - 332

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -